Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Background Obesity is a major risk factor for renal cancer, yet our understanding of its effects on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering these associations is critical, given the growing clinical use of immune checkpoint inhibitors for metastatic disease and...

Full description

Bibliographic Details
Main Authors: Peng Li, Amani Makkouk, Jennifer Gordetsky, Eddy Yang, Lewis Thomas, Lakshminarayanan Nandagopal, Hesham Yasin, Rohan Garje, Shannon K Boi, Rachael M Orlandella, Justin Tyler Gibson, William James Turbitt, Gal Wald, Claire Buchta Rosean, Katlyn E Norris, Megan Bing, Laura Bertrand, Brett P Gross, Dmytro Starenki, Kristine I Farag, Robert E Sorge, James A Brown, David M Lubaroff, Rebecca C Arend, Kenneth Nepple, Tatiana T Marquez-Lago, Lyse A Norian
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000725.full

Internet

https://jitc.bmj.com/content/8/2/e000725.full

Similar Items